Eli Lilly (LLY)
(Delayed Data from NYSE)
$818.93 USD
-10.81 (-1.30%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$818.93 USD
-10.81 (-1.30%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019
by Zacks Equity Research
The big drug stocks are on a strong footing of late. Here are five such picks from the biotech and large-cap pharma space that are expected to do well in 2019 too.
Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.
Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?
by Sweta Killa
Smart Beta ETF report for FLQL
Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug
by Zacks Equity Research
Eli Lilly (LLY) signs a deal with AC Immune to jointly develop Morphomer tau aggregation inhibitors, which have the potential to treat Alzheimer's disease (AD) and other neurodegenerative diseases.
Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800
by Zacks Equity Research
Bristol-Myers (BMY) enters into a collaboration agreement with Vedanta Biosciences to study Opdivo clubbed with the latter's VE800 for treating patients with advanced or metastatic cancers.
The Zacks Analyst Blog Highlights: Eli Lilly, Anthem, BlackRock, CME Group and Southern Company
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Anthem, BlackRock, CME Group and Southern Company
Mallinckrodt (MNK) to Separate Generics & Branded Businesses
by Zacks Equity Research
Mallinckrodt (MNK) announces plans to split its generic and branded businesses into two different companies.
Top Stock Reports for Eli Lilly, Anthem & BlackRock
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly (LLY), Anthem (ANTM) and BlackRock (BLK).
Why Is Lilly (LLY) Up 6.2% Since Last Earnings Report?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Eli Lilly (LLY) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.
The Zacks Analyst Blog Highlights: Verizon, Eli Lilly, Accenture, VMware and Schwab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Verizon, Eli Lilly, Accenture, VMware and Schwab
Incyte (INCY) Announces Positive Data on Jakafi for GVHD
by Zacks Equity Research
Incyte (INCY) announces positive data on lead drug Jakafi at the ASH meet for the indication of acute GVHD.
Top Stock Reports for Verizon, Eli Lilly & Accenture
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Verizon (VZ), Eli Lilly (LLY) and Accenture (ACN).
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $118.64 in the latest trading session, marking a +1.4% move from the prior day.
Lilly (LLY) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Merck (MRK) Receives Approval for 2 HIV Medicines in EU
by Zacks Equity Research
Merck's (MRK) two new HIV drugs, Pifeltro and Delstrigo, containing doravirine, get approval in EU.
4 Big Pharma Stocks to Add to Your Portfolio in December
by Kinjel Shah
The large-cap pharma industry has been on a strong footing lately. Here are four stocks from the space that investors may consider betting on.
Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial
by Zacks Equity Research
Zafgen's (ZFGN) stock plunges significantly as the FDA placed a clinical hold on the company's first trial on experimental diabetes drug, ZGN-1061.
4 Reasons Why Lilly is Up More Than 30% This Year So Far
by Zacks Equity Research
Eli Lilly's (LLY) stock is up 33.7% this year so far. Let us have a look at the reasons for the same.
Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FLQL
Corcept Initiates Phase III Study for Cushing's Syndrome
by Zacks Equity Research
Corcept (CORT) doses first patient in the phase III study of relacorilant for the treatment of Cushing's syndrome.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $115.81 in the latest trading session, marking a +1.74% move from the prior day.
Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings
by Zacks Equity Research
FDA provides updates on Merck (MRK), AstraZeneca (AZN) and Roche (RHHBY) for their cancer drugs. Bayer (BAYRY) reports strong third-quarter results.